Similarly to other plasma p-tau species, p-tau212 is an autopsy-confirmed biomarker that can discriminate CU and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts as well as asymptomatic Down syndrome (aDS) participants from prodromalDS (pDS) and dementiaDS (dDS) [19, 27]. This evidence concerns the gene MAPT and Alzheimer disease.